Cisplatin+Pembrolizumab+RT in Vulvar Cancer

STATUS

Recruiting
End date

Jan 30, 2025
participants needed

24
sponsor

Massachusetts General Hospital

Send

Updated on 19 February 2024

See if I qualify

cancer

blood transfusion

absolute neutrophil count

measurable disease

metastasis

direct bilirubin

pembrolizumab

neutrophil count

squamous cell carcinoma

glomerular filtration rate

hormone therapy

liver metastasis

anticoagulants

endocrine therapy

international normalized ratio

erythropoietin

carcinoma

primary tumor

anticoagulant therapy

total bilirubin

aptt

conjugated bilirubin

cytotoxic chemotherapy

recurrent disease

metastatic squamous cell carcinoma

ffpe

liver metastases

excisional biopsy

international normalized ratio (inr)

vulvar carcinoma

pediatric

cisplatin

vulvar cancer

squamous cell carcinoma of the vulva

radical vulvectomy

Summary

This research is being done to see how well the combination of a standard of care drug, investigational drug, and radiation therapy work against unresectable vulvar squamous cell carcinoma.

This research study involves the following:

Cisplatin (standard of care drug)
Pembrolizumab (investigational drug)
Radiation Therapy (standard of care intervention)

Description

This is a single-arm phase 2 clinical trial involving women with unresectable, incompletely resected, recurrent, or metastatic vulva squamous cell carcinoma. This study combines cisplatin, pembrolizumab, and radiation therapy to see if this combination further increases participants' immune system's efficiency in killing their tumor, and if the combination decreases the chances of participants' cancer coming back.

The research study procedures include screening for eligibility and study treatment including evaluations and follow up visits.

This research study involves the following:

Cisplatin (standard of care drug)
Pembrolizumab (investigational drug)
Radiation Therapy (standard of care intervention)

Participants will receive study treatment for up to 36 weeks and will be followed for up to 3 years.

It is expected that about 24 people will take part in this research study.

Phase II clinical trials test the safety and effectiveness of an investigational drug to learn whether the drug works in treating a specific disease. "Investigational" means that the drug is being studied. The U.S. Food and Drug Administration (FDA) has approved cisplatin as a treatment option for vulva squamous cell carcinoma. The FDA has not approved pembrolizumab for vulva squamous cell carcinoma, but it has been approved for other uses. Cisplatin is a chemotherapy drug and will be given to participants per standard of care.

Radiation therapy will be given to you per standard of care. Pembrolizumab is a drug that may target participants immune systems to increase its efficiency in targeting and killing illnesses and diseases, such as unresectable vulvar squamous cell carcinoma.

Details

Condition	Malignant neoplasm of vulva, Vulvar Squamous Cell Carcinoma
Age	18-100 years
Treatment	Pembrolizumab, Cisplatin, Radiation Therapy
Clinical Study Identifier	NCT04430699
Sponsor	Massachusetts General Hospital
Last Modified on	19 February 2024

How understandable was the trial content above?

Hard to understand

Easy to understand

Eligibility		Yes	No	Not Sure
Inclusion Criteria
	Participants must have histologically or cytologically confirmed unresectable, incompletely resected, recurrent, or metastatic squamous cell carcinoma of the vulva.Patients with unresectable disease are defined as T2 or T3 primary tumors (N0-3, M0) not amenable to surgical resection by standard radical vulvectomy
	Participants must have measurable disease based on RECIST 1.1. Lesions situated in a previously irradiated area are considered measurable if progression has been demonstrated in such lesions
	Have provided archival tumor tissue sample or newly obtained core or excisional biopsy of a tumor lesion not previously irradiated. Formalin-fixed, paraffin embedded (FFPE) tissue blocks are preferred to slides
	Prior therapy: Participants with no prior therapy are eligible and patients with recurrent disease must not have had more than two lines of cytotoxic therapy. Topical or hormonal therapy are not counted towards prior lines. Prior treatment with immunotherapy is allowed, provided treatment was not stopped for grade 2 or greater adverse events
	Time from prior therapy
	Systemic anti-neoplastic therapy: 5 half-lives or 4 weeks, whichever is shorter
	Hormonal therapy is not considered anti-neoplastic therapy
	Radiotherapy: Any prior irradiation is acceptable provided the site being considered for study has not been previously irradiated
	Age 18 years. Because insufficient dosing or adverse event data are currently available on the use of pembrolizumab in combination with cisplatin-sensitized radiation therapy participants <18 years of age, children are excluded. Vulva cancer is rare in the pediatric population
	ECOG performance status of 0 or 1
	Participants must have adequate organ and marrow function as defined below (Table 1)
	Table 1: Adequate Organ Function Laboratory Values
	Hematological
	Absolute neutrophil count (ANC) 1500/L
	Platelets 100 000/L
	Hemoglobin 9.0 g/dL or 5.6 mmol/La
	Renal
	Creatinine OR Measured or calculated b creatinine clearance (GFR can also be used in place of creatinine or CrCl) 1.5 ULN OR 50 mL/min for participant with creatinine
	Hepatic
	Total bilirubin 1.5 ULN OR direct bilirubin ULN for participants with total bilirubin levels >1.5 ULN
	AST (SGOT) and ALT (SGPT) 2.5 ULN (5 ULN for participants with liver metastases)
	Coagulation
	International normalized ratio (INR) OR prothrombin time (PT) Activated partial thromboplastin time (aPTT) 1.5 ULN unless participant is receiving anticoagulant therapy as long as PT or aPTT is within therapeutic range of intended use of anticoagulants
	ALT (SGPT)=alanine aminotransferase (serum glutamic pyruvic transaminase); AST (SGOT)=aspartate aminotransferase (serum glutamic oxaloacetic transaminase); GFR=glomerular filtration rate; ULN=upper limit of normal
	Criteria must be met without erythropoietin dependency and without packed red blood cell (pRBC) transfusion within last 2 weeks
	Creatinine clearance (CrCl) should be calculated per institutional standard
	Note: This table includes eligibility-defining laboratory value requirements for treatment; laboratory value requirements should be adapted according to local regulations and guidelines for the administration of specific chemotherapies
	Participant must be female, and is eligible to participate if she is not pregnant (see Appendix B), not breastfeeding, and at least one of the following conditions applies
	Not a woman of childbearing potential (WOCBP) as defined in Appendix B OR
	A WOCBP must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, during study treatment, and for at least twelve weeks after the last dose of study treatment. Should a woman become pregnant or suspect she is pregnant while she is pregnant while she is participating in this study, she should inform her treating physician immediately
	Ability to understand and the willingness to sign a written informed consent document
Exclusion Criteria
	Patients who in the opinion of the investigator cannot safely receive a minimum of 30 Gy in 10 fractions are not eligible for the trial
	Participants who have received prior systemic anti-cancer therapy including investigational agents within 4 weeks prior to first dose of study treatment. Note: If participant received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting study treatment
	Participants must have recovered from all AEs due to previous therapies to Grade 1 or baseline
	Has received prior radiotherapy within 2 weeks of start of study treatment. Participants must have recovered from all radiation-related toxicities, not require corticosteroids, and not have had radiation pneumonitis. Re-irradiation to a previously treated site will not be permitted
	Participants who have received a live vaccine within 30 days prior to the first dose of study drug. Examples of live vaccines include, but are not limited to, the following: measles, mumps, rubella, varicella/zoster (chicken pox), yellow fever, rabies, Bacillus Calmette-Gurin (BCG), and typhoid vaccine. Seasonal influenza vaccines for injection are generally killed virus vaccines and are allowed; however, intranasal influenza vaccines (eg, FluMist) are live attenuated vaccines and are not allowed
	Participants with vulvar melanomas, sarcomas, extramammary Paget's disease, or basal cell carcinoma
	Participants with a history of gastrointestinal or colovesicular fistulae
	Has active autoimmune disease that has required systemic treatment in the past 2 years (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (eg., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment
	Has known active CNS metastases and/or carcinomatous meningitis. Participants with previously treated brain metastases may participate provided they are radiologically stable, i.e. without evidence of progression for at least 4 weeks by repeat imaging (note that the repeat imaging should be performed during study screening), clinically stable and without requirement of steroid treatment for at least 14 days prior to first dose of study treatment
	Has a history of (non-infectious) pneumonitis that required steroids or has current pneumonitis
	Has an active infection requiring systemic therapy
	Patients with a history of other invasive malignancies, with the exception of nonmelanoma skin cancer, are excluded if there is any evidence of other malignancy being present within the last five years. Patients are also excluded if their previous cancer treatment contraindicates this protocol therapy
	Participants with uncontrolled intercurrent illness
	Participants with psychiatric illness/social situations that would limit compliance with study requirements
	Has a known history of Hepatitis B (defined as Hepatitis B surface antigen [HBsAg] reactive) or known active Hepatitis C virus (defined as HCV RNA [qualitative] is detected) infection. Note: no testing for Hepatitis B and Hepatitis C is required
	Has a known history of active TB (Bacillus Tuberculosis)
	Pregnant or nursing women are excluded from this study because effects of agents used in this study on infants or the developing human fetus are unknown
	Presence of other malignancies unless they are considered cured by patient's oncologist
	Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study, interfere with the subject's participation for the full duration of the study, or is not in the best interest of the subject to participate, in the opinion of the treating investigator
	Has a known history of Human Immunodeficiency Virus (HIV)

How to participate?

Step 1 Connect with a study center

Select a site
Send a message

You have contacted , on

Your message has been sent to the study team at ,

A copy of the message has been sent to your email

What happens next?

You can expect the study team to contact you via email or phone in the next few days.
Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Primary Contact

By sending a message, I agree that my data will be sent to a representative for the selected site and processed in accordance with this website's Privacy Policy (see link in footer).

Step 2 Get screened

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

Step 3 Enroll in the clinical study

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Step 4 Get your study results

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Browse trials for

cancer

blood transfusion

absolute neutrophil count

squamous cell carcinoma

glomerular filtration rate

international normalized ratio

erythropoietin

carcinoma

primary tumor

anticoagulant therapy

total bilirubin

aptt

conjugated bilirubin

cytotoxic chemotherapy

recurrent disease

metastatic squamous cell carcinoma

ffpe

liver metastases

excisional biopsy

international normalized ratio (inr)

squamous cell carcinoma of the vulva

radical vulvectomy

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Study Definition

Wikipedia

Cisplatin+Pembrolizumab+RT in Vulvar Cancer